| 1 | low-dose | 5,273 |
| 2 | high-dose | 4,667 |
| 3 | unfractionated | 760 |
| 4 | pegylated | 728 |
| 5 | low-molecular-weight | 601 |
| 6 | standard-dose | 456 |
| 7 | short-course | 367 |
| 8 | infusional | 179 |
| 9 | full-dose | 172 |
| 10 | ritonavir-boosted | 154 |
| 11 | half-dose | 119 |
| 12 | higher-dose | 119 |
| 13 | lmw | 118 |
| 14 | lower-dose | 111 |
| 15 | split-dose | 103 |
| 16 | alternate-day | 83 |
| 17 | moderate-dose | 82 |
| 18 | high-potency | 80 |
| 19 | adjusted-dose | 79 |
| 20 | medium-dose | 79 |
| 21 | double-dose | 76 |
| 22 | conventional-dose | 73 |
| 23 | benzathine | 67 |
| 24 | dose-adjusted | 62 |
| 25 | high-dosage | 60 |
| 26 | 4-l | 56 |
| 27 | reduced-dose | 55 |
| 28 | intermediate-dose | 51 |
| 29 | low-dosage | 51 |
| 30 | low-fluence | 50 |
| 31 | 2-l | 48 |
| 32 | gaviscon | 46 |
| 33 | chan | 45 |
| 34 | unboosted | 43 |
| 35 | continuous-infusion | 34 |
| 36 | high-dose-rate | 34 |
| 37 | once-yearly | 34 |
| 38 | intensive-dose | 30 |
| 39 | middle-dose | 29 |
| 40 | non-pegylated | 28 |
| 41 | coformulated | 25 |
| 42 | preseasonal | 25 |
| 43 | igm-enriched | 24 |
| 44 | ultra-low-dose | 24 |
| 45 | small-dose | 23 |
| 46 | glutamine-supplemented | 22 |
| 47 | mid-dose | 22 |
| 48 | triweekly | 22 |
| 49 | 0.3-mg | 21 |
| 50 | daylight-mediated | 19 |
| 51 | hospira | 19 |
| 52 | stable-dose | 19 |
| 53 | supplémentation | 19 |
| 54 | minidose | 18 |
| 55 | nonaspirin | 18 |
| 56 | normal-dose | 18 |
| 57 | escalated-dose | 17 |
| 58 | extended-dose | 17 |
| 59 | sugared | 17 |
| 60 | reduced-exposure | 16 |
| 61 | single-course | 16 |
| 62 | solvent-based | 16 |
| 63 | unfractioned | 16 |
| 64 | 2ml | 15 |
| 65 | gauze-based | 15 |
| 66 | n-desmethyl | 15 |
| 67 | nine-hole | 15 |
| 68 | regular-dose | 15 |
| 69 | usual-dose | 15 |
| 70 | 5-methyl | 14 |
| 71 | investigator-selected | 14 |
| 72 | two-pill | 14 |
| 73 | 2-hydroxy | 13 |
| 74 | every-other-week | 13 |
| 75 | low-exposure | 13 |
| 76 | opsonized | 13 |
| 77 | extended-field | 12 |
| 78 | maximum-dose | 12 |
| 79 | pyridinyl | 12 |
| 80 | maximal-dose | 11 |
| 81 | morning-only | 11 |
| 82 | norian | 11 |
| 83 | yinzhihuang | 11 |
| 84 | biopure | 10 |
| 85 | nonprotocol | 10 |
| 86 | response-based | 10 |
| 87 | standard-exposure | 10 |
| 88 | vascu-guard | 10 |
| 89 | 0mg | 9 |
| 90 | biotene | 9 |
| 91 | blu | 9 |
| 92 | cyp3a4-metabolized | 9 |
| 93 | every-3-week | 9 |
| 94 | megadose | 9 |
| 95 | nonpegylated | 9 |
| 96 | phenoxymethyl | 9 |
| 97 | pk-guided | 9 |
| 98 | qishen | 9 |
| 99 | soy/whey | 9 |
| 100 | standard-duration | 9 |
| 101 | fmri-guided | 8 |
| 102 | oestrogen-only | 8 |
| 103 | silylated | 8 |
| 104 | single-inhaler | 8 |
| 105 | standard-intensity | 8 |
| 106 | vbn-assisted | 8 |
| 107 | 0.5m | 7 |
| 108 | 100μg | 7 |
| 109 | 20-μg | 7 |
| 110 | 3.5-mg | 7 |
| 111 | 3alpha-reduced | 7 |
| 112 | 4000iu | 7 |
| 113 | 5-hydroxy | 7 |
| 114 | b-ultrasound-guided | 7 |
| 115 | low‑dose | 7 |
| 116 | lutonix | 7 |
| 117 | moderate-dosage | 7 |
| 118 | non-paa-treated | 7 |
| 119 | paa-treated | 7 |
| 120 | preconception-initiated | 7 |
| 121 | sulphadoxine | 7 |
| 122 | very-low-dose | 7 |
| 123 | 1-mg/kg | 6 |
| 124 | 2×100-mg | 6 |
| 125 | 9-hole | 6 |
| 126 | carboplatin-pegylated | 6 |
| 127 | cip/mtz | 6 |
| 128 | efavirenz-free | 6 |
| 129 | hfa-propelled | 6 |
| 130 | high-fluence | 6 |
| 131 | increased-dose | 6 |
| 132 | no-iv | 6 |
| 133 | non-wbc-reduced | 6 |
| 134 | off/on | 6 |
| 135 | once-per-week | 6 |
| 136 | poldine | 6 |
| 137 | single-coil | 6 |
| 138 | triple-dose | 6 |
| 139 | ultralow-dose | 6 |
| 140 | unaccepting | 6 |
| 141 | 14w | 5 |
| 142 | 300-u | 5 |
| 143 | 30μg | 5 |
| 144 | 80-μg | 5 |
| 145 | 9-hydroxy | 5 |
| 146 | alternate-week | 5 |
| 147 | c-stem | 5 |
| 148 | candys | 5 |
| 149 | corresponding-dose | 5 |
| 150 | cysteine-free | 5 |
| 151 | double-bolus | 5 |
| 152 | european-marketed | 5 |
| 153 | hib-menc | 5 |
| 154 | kollidon® | 5 |
| 155 | mid-potency | 5 |
| 156 | nonextrafine | 5 |
| 157 | pharmaconutrition-supplemented | 5 |
| 158 | porcilis | 5 |
| 159 | prophylactic-dose | 5 |
| 160 | reduced-fluence | 5 |
| 161 | rumination-focused | 5 |
| 162 | sehi | 5 |
| 163 | staff-led | 5 |
| 164 | synthetic-source | 5 |
| 165 | urease-deficient | 5 |
| 166 | 1-gallon | 4 |
| 167 | 600-μg | 4 |
| 168 | 700-microg | 4 |
| 169 | afxl-assisted | 4 |
| 170 | buffy-coat-reduced | 4 |
| 171 | conventional-start | 4 |
| 172 | decrescendo | 4 |
| 173 | dual-hemisphere | 4 |
| 174 | estradiol-based | 4 |
| 175 | every-4-week | 4 |
| 176 | full-laxative | 4 |
| 177 | highdose | 4 |
| 178 | immune-enhanced | 4 |
| 179 | l-asparaginase-based | 4 |
| 180 | mini-dose | 4 |
| 181 | mmlv | 4 |
| 182 | niox | 4 |
| 183 | nociceptin/orphanin | 4 |
| 184 | non-boosted | 4 |
| 185 | noninactivated | 4 |
| 186 | prrsv-specific | 4 |
| 187 | standard-fluence | 4 |
| 188 | stress-dose | 4 |
| 189 | u.s.-approved | 4 |
| 190 | ultra-low-molecular-weight | 4 |
| 191 | vectormune | 4 |
| 192 | 1.0-mg/kg | 3 |
| 193 | 1.75-mg | 3 |
| 194 | 4'-hydroxyphenyl | 3 |
| 195 | 5-field | 3 |
| 196 | 5-fu+low-dose | 3 |
| 197 | 6.8-g | 3 |
| 198 | algorithm-consistent | 3 |
| 199 | aminoacid-enriched | 3 |
| 200 | anthracycline-only | 3 |
| 201 | aspirin-er | 3 |
| 202 | baypress | 3 |
| 203 | buchang | 3 |
| 204 | ceram-x | 3 |
| 205 | chickpea-based | 3 |
| 206 | desogestrel-containing | 3 |
| 207 | double-arc | 3 |
| 208 | five-field | 3 |
| 209 | fukushima-derived | 3 |
| 210 | high-compliance | 3 |
| 211 | high-maintenance-dose | 3 |
| 212 | high-pull | 3 |
| 213 | huadananshen | 3 |
| 214 | locally-used | 3 |
| 215 | micro-dose | 3 |
| 216 | moderate-potency | 3 |
| 217 | mono-component | 3 |
| 218 | morning-dosed | 3 |
| 219 | nighttime-release | 3 |
| 220 | non-ca | 3 |
| 221 | non-cpg | 3 |
| 222 | non-pt-based | 3 |
| 223 | nonloading | 3 |
| 224 | not-complicated | 3 |
| 225 | ntrk1_ | 3 |
| 226 | opsonised | 3 |
| 227 | para-hydroxy | 3 |
| 228 | parent-enhanced | 3 |
| 229 | restricted-dose | 3 |
| 230 | ritonavir-enhanced | 3 |
| 231 | semi-bespoke | 3 |
| 232 | smartphone-supplemented | 3 |
| 233 | sofzia-preserved | 3 |
| 234 | systemically-used | 3 |
| 235 | transcolonic | 3 |
| 236 | z-cut | 3 |
| 237 | 1-drop | 2 |
| 238 | 1.2-mg | 2 |
| 239 | 100-µm | 2 |
| 240 | 135-microg/kg | 2 |
| 241 | 2.0g | 2 |
| 242 | 25-o-desacetyl | 2 |
| 243 | 3-ppm | 2 |
| 244 | 45-gy | 2 |
| 245 | 50-mg/day | 2 |
| 246 | 50-µg | 2 |
| 247 | 500iu | 2 |
| 248 | 53,565 | 2 |
| 249 | 54-mg | 2 |
| 250 | 70u/kg | 2 |
| 251 | 75μm | 2 |
| 252 | 7mg/kg | 2 |
| 253 | 9-field | 2 |
| 254 | 90-mg/day | 2 |
| 255 | aai-guided | 2 |
| 256 | acei/ | 2 |
| 257 | agncs/hairpin | 2 |
| 258 | ala-based | 2 |
| 259 | aminoacid-free | 2 |
| 260 | antivitamin-k | 2 |
| 261 | arginine-supplementation | 2 |
| 262 | arrhythmia-triggered | 2 |
| 263 | azt- | 2 |
| 264 | barbiturate-containing | 2 |
| 265 | behenoyl | 2 |
| 266 | benzathin | 2 |
| 267 | biofeedback-enhanced | 2 |
| 268 | bu-based | 2 |
| 269 | bupivacaine/hydromorphone | 2 |
| 270 | buzhong | 2 |
| 271 | c17alpha-alkylated | 2 |
| 272 | calcimycin-stimulated | 2 |
| 273 | cetacaine | 2 |
| 274 | cisplatin/ | 2 |
| 275 | co-administrating | 2 |
| 276 | cobicistat-boosted | 2 |
| 277 | cocaine-containing | 2 |
| 278 | copperbearing | 2 |
| 279 | dose-intensifying | 2 |
| 280 | esencial | 2 |
| 281 | eudragit-l-coated | 2 |
| 282 | every-12-week | 2 |
| 283 | ezetimibe/ | 2 |
| 284 | f-based | 2 |
| 285 | five-times-daily | 2 |
| 286 | flurouracil-based | 2 |
| 287 | four-cycle | 2 |
| 288 | glutamine-added | 2 |
| 289 | hbr-pre-treated | 2 |
| 290 | hi-trap | 2 |
| 291 | inr-adjusted | 2 |
| 292 | inverse-planned | 2 |
| 293 | iopromide-based | 2 |
| 294 | kangliu | 2 |
| 295 | leucovorin-modulated | 2 |
| 296 | losartan/ | 2 |
| 297 | low-dose/no | 2 |
| 298 | mdd/no | 2 |
| 299 | mechanico-chemical | 2 |
| 300 | methotrexate- | 2 |
| 301 | methotrexate/vinblastine/doxorubicin/cisplatin | 2 |
| 302 | microemulsified | 2 |
| 303 | mid-intensity | 2 |
| 304 | monitored-dose | 2 |
| 305 | n/l-type | 2 |
| 306 | non-lipophilic | 2 |
| 307 | non-olmesartan | 2 |
| 308 | non-secondary | 2 |
| 309 | nonimmunosuppressive | 2 |
| 310 | nonuroselective | 2 |
| 311 | ovariectomised+60mg/kg | 2 |
| 312 | palitaxel | 2 |
| 313 | peg-liposomal | 2 |
| 314 | pegilated | 2 |
| 315 | photofrin™ | 2 |
| 316 | pocal | 2 |
| 317 | polysulfated | 2 |
| 318 | precirol | 2 |
| 319 | preleukapheresis | 2 |
| 320 | preradiation | 2 |
| 321 | ps-supported | 2 |
| 322 | pump-driven | 2 |
| 323 | sodic | 2 |
| 324 | sorafenib+ | 2 |
| 325 | spect/low-dose | 2 |
| 326 | ss/tr | 2 |
| 327 | standard-maintenance-dose | 2 |
| 328 | sufentanil-propofol | 2 |
| 329 | taxol+ | 2 |
| 330 | tdf+ | 2 |
| 331 | temoporfin | 2 |
| 332 | tenofovir/ | 2 |
| 333 | vasopressinase-resistant | 2 |
| 334 | ventilator-derived | 2 |
| 335 | whole-neck | 2 |
| 336 | β₃-adrenoceptor-selective | 2 |
| 337 | 0.03iu/ml | 1 |
| 338 | 0.1-10mm | 1 |
| 339 | 0.5mm/l | 1 |
| 340 | 0.625-mg/day | 1 |
| 341 | 0.97* | 1 |
| 342 | 1-100mg/d | 1 |
| 343 | 1-hexylcarbamoyl | 1 |
| 344 | 1-silyl-substituted | 1 |
| 345 | 10-iu/cc | 1 |
| 346 | 10.000e | 1 |
| 347 | 100u/kg | 1 |
| 348 | 12,324 | 1 |
| 349 | 12.2±0.5 | 1 |
| 350 | 130-nanometer | 1 |
| 351 | 135/0.5 | 1 |
| 352 | 135/0.75 | 1 |
| 353 | 14-3-3σ-negative | 1 |
| 354 | 14-3-3σ-positive | 1 |
| 355 | 14-peptide | 1 |
| 356 | 158,054 | 1 |
| 357 | 19,872 | 1 |
| 358 | 1:1.850,000 | 1 |
| 359 | 1:1.850.000 | 1 |
| 360 | 2-size | 1 |
| 361 | 20mg/m2 | 1 |
| 362 | 225,952 | 1 |
| 363 | 25-o-desacetyl- | 1 |
| 364 | 25-o-desacteyl | 1 |
| 365 | 25/678 | 1 |
| 366 | 284:1008-1015 | 1 |
| 367 | 2nrti+ | 1 |
| 368 | 2μg | 1 |
| 369 | 3+1l | 1 |
| 370 | 30/25/45 | 1 |
| 371 | 32,050 | 1 |
| 372 | 333-mg | 1 |
| 373 | 350-microg | 1 |
| 374 | 36,037 | 1 |
| 375 | 387,268 | 1 |
| 376 | 3d-crt-based | 1 |
| 377 | 4,927 | 1 |
| 378 | 4-field | 1 |
| 379 | 4.1±2.9 | 1 |
| 380 | 43,810 | 1 |
| 381 | 44-microg | 1 |
| 382 | 49/103 | 1 |
| 383 | 5-kda | 1 |
| 384 | 500iu/g | 1 |
| 385 | 5389 | 1 |
| 386 | 60/5/35 | 1 |
| 387 | 700-900-μm | 1 |
| 388 | 74-gy | 1 |
| 389 | 8-isoprostan- | 1 |
| 390 | 8-methoxsalen | 1 |
| 391 | 900-1200/micrograms | 1 |
| 392 | 95,765 | 1 |
| 393 | 99,926 | 1 |
| 394 | 99tcm-labelled | 1 |
| 395 | ac+ | 1 |
| 396 | actief | 1 |
| 397 | adequate-to-low | 1 |
| 398 | adjustable-dose | 1 |
| 399 | afxl-mediated | 1 |
| 400 | ala-mediated | 1 |
| 401 | alcohol/ | 1 |
| 402 | aliskiren/ | 1 |
| 403 | alpha-amino-p-hydroxybenzyl | 1 |
| 404 | alpha-fox3000 | 1 |
| 405 | analgesia.continuous | 1 |
| 406 | anti-fxa-based | 1 |
| 407 | anti-mhc-induced | 1 |
| 408 | antihaemophilic | 1 |
| 409 | antistaphlococcal | 1 |
| 410 | appropriate/inappropriate | 1 |
| 411 | appropriately-implemented | 1 |
| 412 | arb/ | 1 |
| 413 | aspirin/low-dose | 1 |
| 414 | aspiriner | 1 |
| 415 | atazanavir/ | 1 |
| 416 | atv/r+tdf/ | 1 |
| 417 | aza/oral | 1 |
| 418 | azt+3tc+an | 1 |
| 419 | baby-dose | 1 |
| 420 | banzanthine | 1 |
| 421 | benzanthine | 1 |
| 422 | beta-hydroxyacid | 1 |
| 423 | biafine | 1 |
| 424 | calf-thigh-length | 1 |
| 425 | caprie-study | 1 |
| 426 | carboplatin/pegylated | 1 |
| 427 | cbz→ | 1 |
| 428 | ceftazidime+ | 1 |
| 429 | challenge-proven | 1 |
| 430 | cheliceral | 1 |
| 431 | chinese-authored | 1 |
| 432 | chronice | 1 |
| 433 | cisplatin/iv | 1 |
| 434 | clopidogrel/dummy | 1 |
| 435 | cognitively-focused | 1 |
| 436 | compañeros | 1 |
| 437 | compounds׳ | 1 |
| 438 | control-side | 1 |
| 439 | cooperativa | 1 |
| 440 | corrispective | 1 |
| 441 | cotex | 1 |
| 442 | cp-focused | 1 |
| 443 | creams.high-concentration | 1 |
| 444 | ct1-2n0 | 1 |
| 445 | cut-off=intermediate-level | 1 |
| 446 | cut-off=low-level | 1 |
| 447 | d-panor | 1 |
| 448 | d4t+3tc+an | 1 |
| 449 | delta-tocotrienol+11mg/kg | 1 |
| 450 | dermatotoxin | 1 |
| 451 | dithiolated | 1 |
| 452 | dl-15-methyl | 1 |
| 453 | dopamine/ | 1 |
| 454 | dose-adapted | 1 |
| 455 | double-dosed | 1 |
| 456 | dual-arc | 1 |
| 457 | easy-to-store | 1 |
| 458 | ebrtor | 1 |
| 459 | eclectic/unspecified | 1 |
| 460 | elastic-tubing | 1 |
| 461 | electroforesis | 1 |
| 462 | eliminating-avoiding | 1 |
| 463 | elliciting | 1 |
| 464 | elusion™ | 1 |
| 465 | epirubicin-cisplatin-continuous | 1 |
| 466 | ern/ | 1 |
| 467 | eubiotic | 1 |
| 468 | fine-gauge | 1 |
| 469 | firstgeneration | 1 |
| 470 | fl-assisted | 1 |
| 471 | full-treatment | 1 |
| 472 | gabapentin- | 1 |
| 473 | galactose-modified | 1 |
| 474 | genentech-sponsored | 1 |
| 475 | gfp-human | 1 |
| 476 | hanchuan | 1 |
| 477 | headaches.for | 1 |
| 478 | hema-containing | 1 |
| 479 | heparin/low-molecular-weight | 1 |
| 480 | high-nacl-intake | 1 |
| 481 | high-protein/calorie | 1 |
| 482 | higher-efficacy | 1 |
| 483 | hvj-anionic | 1 |
| 484 | hyperproduced | 1 |
| 485 | immunosuppressant/anti-inflammatory | 1 |
| 486 | inf+ | 1 |
| 487 | insulin-titrated | 1 |
| 488 | intensity-deviant | 1 |
| 489 | interferon/pegylated | 1 |
| 490 | intermediate-/high-potency | 1 |
| 491 | intrapartum/newborn | 1 |
| 492 | investigator-approved | 1 |
| 493 | ipl-assisted | 1 |
| 494 | irbesartan-an | 1 |
| 495 | jak1-mediated | 1 |
| 496 | kefar | 1 |
| 497 | keratotic-atrophic-erosive | 1 |
| 498 | kevlar | 1 |
| 499 | kfar | 1 |
| 500 | kystic | 1 |
| 501 | l-alanyl-l-glutamine-supplemented | 1 |
| 502 | lantiobiotic | 1 |
| 503 | lisinopril/ | 1 |
| 504 | litre-1 | 1 |
| 505 | long-acting-intramuscular | 1 |
| 506 | longwave | 1 |
| 507 | low-nacl-intake | 1 |
| 508 | luciferase-expressing | 1 |
| 509 | lyso-thermosensitive | 1 |
| 510 | masuri | 1 |
| 511 | mek-inhibitor | 1 |
| 512 | methods-low-dose | 1 |
| 513 | microneedling-assisted | 1 |
| 514 | micronisedfeno | 1 |
| 515 | mirabilis.the | 1 |
| 516 | mn-assisted | 1 |
| 517 | moderate-to-high-dose | 1 |
| 518 | monooleate-modified | 1 |
| 519 | monthly-dose | 1 |
| 520 | more-soluble | 1 |
| 521 | mtx+high-dose | 1 |
| 522 | n=3332 | 1 |
| 523 | n=787 | 1 |
| 524 | narlaprevir/pegylated | 1 |
| 525 | nct01452243 | 1 |
| 526 | ngm-containing | 1 |
| 527 | nightmare-focused | 1 |
| 528 | nir-responsive | 1 |
| 529 | no-s. | 1 |
| 530 | non-baseline-adjusted | 1 |
| 531 | non-cabl-inhibitor | 1 |
| 532 | non-cardio-selective | 1 |
| 533 | non-fractional | 1 |
| 534 | non-fractioned | 1 |
| 535 | non-pegilated | 1 |
| 536 | nonamino | 1 |
| 537 | nonantioxidant | 1 |
| 538 | noniodinized | 1 |
| 539 | nonmaintained | 1 |
| 540 | nonopsonized | 1 |
| 541 | nosocomiales | 1 |
| 542 | nsaids-especially | 1 |
| 543 | ouverte | 1 |
| 544 | oxaliplatin/lv/infusional | 1 |
| 545 | papain-urea | 1 |
| 546 | peg- | 1 |
| 547 | peg-ifn/ | 1 |
| 548 | peg-α-2b | 1 |
| 549 | pf-mouse | 1 |
| 550 | pha-mediated | 1 |
| 551 | pharmacist-participated | 1 |
| 552 | pharmacogenomics-based | 1 |
| 553 | phenoxymethyl- | 1 |
| 554 | phenytoin-induced | 1 |
| 555 | pinggan | 1 |
| 556 | platinum/ | 1 |
| 557 | platinum/infusional | 1 |
| 558 | potassium-wasting | 1 |
| 559 | previous-cycle | 1 |
| 560 | prior/current | 1 |
| 561 | procaine-benzyl | 1 |
| 562 | promiseb® | 1 |
| 563 | prophylactic/low-dose | 1 |
| 564 | prophylactively | 1 |
| 565 | pyridinal | 1 |
| 566 | radachlorin-mediated | 1 |
| 567 | radiation/oral | 1 |
| 568 | radioinert | 1 |
| 569 | ratio-adjusted | 1 |
| 570 | rbp-supported | 1 |
| 571 | re-formulating | 1 |
| 572 | re-re-treatment | 1 |
| 573 | res±perioperative | 1 |
| 574 | review.peri-implantation | 1 |
| 575 | revivable | 1 |
| 576 | ribavirin-pegylated | 1 |
| 577 | ribavirine-standard | 1 |
| 578 | risk-indicated | 1 |
| 579 | rpv+ftc/ | 1 |
| 580 | rs-expressing | 1 |
| 581 | rt-bound | 1 |
| 582 | sag-induced | 1 |
| 583 | same-time-daily | 1 |
| 584 | secura | 1 |
| 585 | short-term/no | 1 |
| 586 | simvastatin/ | 1 |
| 587 | site-activated | 1 |
| 588 | small-particle-size | 1 |
| 589 | speech-enabled | 1 |
| 590 | spironolactone-analogue | 1 |
| 591 | standard-lose | 1 |
| 592 | stellarex | 1 |
| 593 | subcutanous | 1 |
| 594 | subtitled | 1 |
| 595 | sucabitril | 1 |
| 596 | supraselective | 1 |
| 597 | surgimesh | 1 |
| 598 | svv-based | 1 |
| 599 | telomere-targeting | 1 |
| 600 | tenofovir+ | 1 |
| 601 | test-side | 1 |
| 602 | testosterone-like | 1 |
| 603 | time-modified | 1 |
| 604 | tolerability-adapted | 1 |
| 605 | tor-i/reduced | 1 |
| 606 | tor-i/standard-dose | 1 |
| 607 | traditional/customized | 1 |
| 608 | trichdb | 1 |
| 609 | twenty-unit | 1 |
| 610 | twenty-week | 1 |
| 611 | tyrosinkinase-inhibitor | 1 |
| 612 | ultra-potent | 1 |
| 613 | ultrafluid | 1 |
| 614 | undeuterated | 1 |
| 615 | usual-intensity | 1 |
| 616 | vector-delivered | 1 |
| 617 | verteporfin/sham | 1 |
| 618 | vsv-induced | 1 |
| 619 | vtd-induced | 1 |
| 620 | xeliri- | 1 |
| 621 | yifei | 1 |
| 622 | zolpidem/ | 1 |
| 623 | ≥64-multidetector | 1 |
| 1 | 0.03iu/ml | 1 |
| 2 | 0.1-10mm | 1 |
| 3 | 0.3-mg | 21 |
| 4 | 0.5m | 7 |
| 5 | 0.5mm/l | 1 |
| 6 | 0.625-mg/day | 1 |
| 7 | 0.97* | 1 |
| 8 | 0mg | 9 |
| 9 | 1-100mg/d | 1 |
| 10 | 1-drop | 2 |
| 11 | 1-gallon | 4 |
| 12 | 1-hexylcarbamoyl | 1 |
| 13 | 1-mg/kg | 6 |
| 14 | 1-silyl-substituted | 1 |
| 15 | 1.0-mg/kg | 3 |
| 16 | 1.2-mg | 2 |
| 17 | 1.75-mg | 3 |
| 18 | 10-iu/cc | 1 |
| 19 | 10.000e | 1 |
| 20 | 100-µm | 2 |
| 21 | 100u/kg | 1 |
| 22 | 100μg | 7 |
| 23 | 12,324 | 1 |
| 24 | 12.2±0.5 | 1 |
| 25 | 130-nanometer | 1 |
| 26 | 135-microg/kg | 2 |
| 27 | 135/0.5 | 1 |
| 28 | 135/0.75 | 1 |
| 29 | 14-3-3σ-negative | 1 |
| 30 | 14-3-3σ-positive | 1 |
| 31 | 14-peptide | 1 |
| 32 | 14w | 5 |
| 33 | 158,054 | 1 |
| 34 | 19,872 | 1 |
| 35 | 1:1.850,000 | 1 |
| 36 | 1:1.850.000 | 1 |
| 37 | 2-hydroxy | 13 |
| 38 | 2-l | 48 |
| 39 | 2-size | 1 |
| 40 | 2.0g | 2 |
| 41 | 20-μg | 7 |
| 42 | 20mg/m2 | 1 |
| 43 | 225,952 | 1 |
| 44 | 25-o-desacetyl | 2 |
| 45 | 25-o-desacetyl- | 1 |
| 46 | 25-o-desacteyl | 1 |
| 47 | 25/678 | 1 |
| 48 | 284:1008-1015 | 1 |
| 49 | 2ml | 15 |
| 50 | 2nrti+ | 1 |
| 51 | 2×100-mg | 6 |
| 52 | 2μg | 1 |
| 53 | 3+1l | 1 |
| 54 | 3-ppm | 2 |
| 55 | 3.5-mg | 7 |
| 56 | 30/25/45 | 1 |
| 57 | 300-u | 5 |
| 58 | 30μg | 5 |
| 59 | 32,050 | 1 |
| 60 | 333-mg | 1 |
| 61 | 350-microg | 1 |
| 62 | 36,037 | 1 |
| 63 | 387,268 | 1 |
| 64 | 3alpha-reduced | 7 |
| 65 | 3d-crt-based | 1 |
| 66 | 4'-hydroxyphenyl | 3 |
| 67 | 4,927 | 1 |
| 68 | 4-field | 1 |
| 69 | 4-l | 56 |
| 70 | 4.1±2.9 | 1 |
| 71 | 4000iu | 7 |
| 72 | 43,810 | 1 |
| 73 | 44-microg | 1 |
| 74 | 45-gy | 2 |
| 75 | 49/103 | 1 |
| 76 | 5-field | 3 |
| 77 | 5-fu+low-dose | 3 |
| 78 | 5-hydroxy | 7 |
| 79 | 5-kda | 1 |
| 80 | 5-methyl | 14 |
| 81 | 50-mg/day | 2 |
| 82 | 50-µg | 2 |
| 83 | 500iu | 2 |
| 84 | 500iu/g | 1 |
| 85 | 53,565 | 2 |
| 86 | 5389 | 1 |
| 87 | 54-mg | 2 |
| 88 | 6.8-g | 3 |
| 89 | 60/5/35 | 1 |
| 90 | 600-μg | 4 |
| 91 | 700-900-μm | 1 |
| 92 | 700-microg | 4 |
| 93 | 70u/kg | 2 |
| 94 | 74-gy | 1 |
| 95 | 75μm | 2 |
| 96 | 7mg/kg | 2 |
| 97 | 8-isoprostan- | 1 |
| 98 | 8-methoxsalen | 1 |
| 99 | 80-μg | 5 |
| 100 | 9-field | 2 |
| 101 | 9-hole | 6 |
| 102 | 9-hydroxy | 5 |
| 103 | 90-mg/day | 2 |
| 104 | 900-1200/micrograms | 1 |
| 105 | 95,765 | 1 |
| 106 | 99,926 | 1 |
| 107 | 99tcm-labelled | 1 |
| 108 | aai-guided | 2 |
| 109 | ac+ | 1 |
| 110 | acei/ | 2 |
| 111 | actief | 1 |
| 112 | adequate-to-low | 1 |
| 113 | adjustable-dose | 1 |
| 114 | adjusted-dose | 79 |
| 115 | afxl-assisted | 4 |
| 116 | afxl-mediated | 1 |
| 117 | agncs/hairpin | 2 |
| 118 | ala-based | 2 |
| 119 | ala-mediated | 1 |
| 120 | alcohol/ | 1 |
| 121 | algorithm-consistent | 3 |
| 122 | aliskiren/ | 1 |
| 123 | alpha-amino-p-hydroxybenzyl | 1 |
| 124 | alpha-fox3000 | 1 |
| 125 | alternate-day | 83 |
| 126 | alternate-week | 5 |
| 127 | aminoacid-enriched | 3 |
| 128 | aminoacid-free | 2 |
| 129 | analgesia.continuous | 1 |
| 130 | anthracycline-only | 3 |
| 131 | anti-fxa-based | 1 |
| 132 | anti-mhc-induced | 1 |
| 133 | antihaemophilic | 1 |
| 134 | antistaphlococcal | 1 |
| 135 | antivitamin-k | 2 |
| 136 | appropriate/inappropriate | 1 |
| 137 | appropriately-implemented | 1 |
| 138 | arb/ | 1 |
| 139 | arginine-supplementation | 2 |
| 140 | arrhythmia-triggered | 2 |
| 141 | aspirin-er | 3 |
| 142 | aspirin/low-dose | 1 |
| 143 | aspiriner | 1 |
| 144 | atazanavir/ | 1 |
| 145 | atv/r+tdf/ | 1 |
| 146 | aza/oral | 1 |
| 147 | azt+3tc+an | 1 |
| 148 | azt- | 2 |
| 149 | b-ultrasound-guided | 7 |
| 150 | baby-dose | 1 |
| 151 | banzanthine | 1 |
| 152 | barbiturate-containing | 2 |
| 153 | baypress | 3 |
| 154 | behenoyl | 2 |
| 155 | benzanthine | 1 |
| 156 | benzathin | 2 |
| 157 | benzathine | 67 |
| 158 | beta-hydroxyacid | 1 |
| 159 | biafine | 1 |
| 160 | biofeedback-enhanced | 2 |
| 161 | biopure | 10 |
| 162 | biotene | 9 |
| 163 | blu | 9 |
| 164 | bu-based | 2 |
| 165 | buchang | 3 |
| 166 | buffy-coat-reduced | 4 |
| 167 | bupivacaine/hydromorphone | 2 |
| 168 | buzhong | 2 |
| 169 | c-stem | 5 |
| 170 | c17alpha-alkylated | 2 |
| 171 | calcimycin-stimulated | 2 |
| 172 | calf-thigh-length | 1 |
| 173 | candys | 5 |
| 174 | caprie-study | 1 |
| 175 | carboplatin-pegylated | 6 |
| 176 | carboplatin/pegylated | 1 |
| 177 | cbz→ | 1 |
| 178 | ceftazidime+ | 1 |
| 179 | ceram-x | 3 |
| 180 | cetacaine | 2 |
| 181 | challenge-proven | 1 |
| 182 | chan | 45 |
| 183 | cheliceral | 1 |
| 184 | chickpea-based | 3 |
| 185 | chinese-authored | 1 |
| 186 | chronice | 1 |
| 187 | cip/mtz | 6 |
| 188 | cisplatin/ | 2 |
| 189 | cisplatin/iv | 1 |
| 190 | clopidogrel/dummy | 1 |
| 191 | co-administrating | 2 |
| 192 | cobicistat-boosted | 2 |
| 193 | cocaine-containing | 2 |
| 194 | coformulated | 25 |
| 195 | cognitively-focused | 1 |
| 196 | compañeros | 1 |
| 197 | compounds׳ | 1 |
| 198 | continuous-infusion | 34 |
| 199 | control-side | 1 |
| 200 | conventional-dose | 73 |
| 201 | conventional-start | 4 |
| 202 | cooperativa | 1 |
| 203 | copperbearing | 2 |
| 204 | corresponding-dose | 5 |
| 205 | corrispective | 1 |
| 206 | cotex | 1 |
| 207 | cp-focused | 1 |
| 208 | creams.high-concentration | 1 |
| 209 | ct1-2n0 | 1 |
| 210 | cut-off=intermediate-level | 1 |
| 211 | cut-off=low-level | 1 |
| 212 | cyp3a4-metabolized | 9 |
| 213 | cysteine-free | 5 |
| 214 | d-panor | 1 |
| 215 | d4t+3tc+an | 1 |
| 216 | daylight-mediated | 19 |
| 217 | decrescendo | 4 |
| 218 | delta-tocotrienol+11mg/kg | 1 |
| 219 | dermatotoxin | 1 |
| 220 | desogestrel-containing | 3 |
| 221 | dithiolated | 1 |
| 222 | dl-15-methyl | 1 |
| 223 | dopamine/ | 1 |
| 224 | dose-adapted | 1 |
| 225 | dose-adjusted | 62 |
| 226 | dose-intensifying | 2 |
| 227 | double-arc | 3 |
| 228 | double-bolus | 5 |
| 229 | double-dose | 76 |
| 230 | double-dosed | 1 |
| 231 | dual-arc | 1 |
| 232 | dual-hemisphere | 4 |
| 233 | easy-to-store | 1 |
| 234 | ebrtor | 1 |
| 235 | eclectic/unspecified | 1 |
| 236 | efavirenz-free | 6 |
| 237 | elastic-tubing | 1 |
| 238 | electroforesis | 1 |
| 239 | eliminating-avoiding | 1 |
| 240 | elliciting | 1 |
| 241 | elusion™ | 1 |
| 242 | epirubicin-cisplatin-continuous | 1 |
| 243 | ern/ | 1 |
| 244 | escalated-dose | 17 |
| 245 | esencial | 2 |
| 246 | estradiol-based | 4 |
| 247 | eubiotic | 1 |
| 248 | eudragit-l-coated | 2 |
| 249 | european-marketed | 5 |
| 250 | every-12-week | 2 |
| 251 | every-3-week | 9 |
| 252 | every-4-week | 4 |
| 253 | every-other-week | 13 |
| 254 | extended-dose | 17 |
| 255 | extended-field | 12 |
| 256 | ezetimibe/ | 2 |
| 257 | f-based | 2 |
| 258 | fine-gauge | 1 |
| 259 | firstgeneration | 1 |
| 260 | five-field | 3 |
| 261 | five-times-daily | 2 |
| 262 | fl-assisted | 1 |
| 263 | flurouracil-based | 2 |
| 264 | fmri-guided | 8 |
| 265 | four-cycle | 2 |
| 266 | fukushima-derived | 3 |
| 267 | full-dose | 172 |
| 268 | full-laxative | 4 |
| 269 | full-treatment | 1 |
| 270 | gabapentin- | 1 |
| 271 | galactose-modified | 1 |
| 272 | gauze-based | 15 |
| 273 | gaviscon | 46 |
| 274 | genentech-sponsored | 1 |
| 275 | gfp-human | 1 |
| 276 | glutamine-added | 2 |
| 277 | glutamine-supplemented | 22 |
| 278 | half-dose | 119 |
| 279 | hanchuan | 1 |
| 280 | hbr-pre-treated | 2 |
| 281 | headaches.for | 1 |
| 282 | hema-containing | 1 |
| 283 | heparin/low-molecular-weight | 1 |
| 284 | hfa-propelled | 6 |
| 285 | hi-trap | 2 |
| 286 | hib-menc | 5 |
| 287 | high-compliance | 3 |
| 288 | high-dosage | 60 |
| 289 | high-dose | 4,667 |
| 290 | high-dose-rate | 34 |
| 291 | high-fluence | 6 |
| 292 | high-maintenance-dose | 3 |
| 293 | high-nacl-intake | 1 |
| 294 | high-potency | 80 |
| 295 | high-protein/calorie | 1 |
| 296 | high-pull | 3 |
| 297 | highdose | 4 |
| 298 | higher-dose | 119 |
| 299 | higher-efficacy | 1 |
| 300 | hospira | 19 |
| 301 | huadananshen | 3 |
| 302 | hvj-anionic | 1 |
| 303 | hyperproduced | 1 |
| 304 | igm-enriched | 24 |
| 305 | immune-enhanced | 4 |
| 306 | immunosuppressant/anti-inflammatory | 1 |
| 307 | increased-dose | 6 |
| 308 | inf+ | 1 |
| 309 | infusional | 179 |
| 310 | inr-adjusted | 2 |
| 311 | insulin-titrated | 1 |
| 312 | intensity-deviant | 1 |
| 313 | intensive-dose | 30 |
| 314 | interferon/pegylated | 1 |
| 315 | intermediate-/high-potency | 1 |
| 316 | intermediate-dose | 51 |
| 317 | intrapartum/newborn | 1 |
| 318 | inverse-planned | 2 |
| 319 | investigator-approved | 1 |
| 320 | investigator-selected | 14 |
| 321 | iopromide-based | 2 |
| 322 | ipl-assisted | 1 |
| 323 | irbesartan-an | 1 |
| 324 | jak1-mediated | 1 |
| 325 | kangliu | 2 |
| 326 | kefar | 1 |
| 327 | keratotic-atrophic-erosive | 1 |
| 328 | kevlar | 1 |
| 329 | kfar | 1 |
| 330 | kollidon® | 5 |
| 331 | kystic | 1 |
| 332 | l-alanyl-l-glutamine-supplemented | 1 |
| 333 | l-asparaginase-based | 4 |
| 334 | lantiobiotic | 1 |
| 335 | leucovorin-modulated | 2 |
| 336 | lisinopril/ | 1 |
| 337 | litre-1 | 1 |
| 338 | lmw | 118 |
| 339 | locally-used | 3 |
| 340 | long-acting-intramuscular | 1 |
| 341 | longwave | 1 |
| 342 | losartan/ | 2 |
| 343 | low-dosage | 51 |
| 344 | low-dose | 5,273 |
| 345 | low-dose/no | 2 |
| 346 | low-exposure | 13 |
| 347 | low-fluence | 50 |
| 348 | low-molecular-weight | 601 |
| 349 | low-nacl-intake | 1 |
| 350 | lower-dose | 111 |
| 351 | low‑dose | 7 |
| 352 | luciferase-expressing | 1 |
| 353 | lutonix | 7 |
| 354 | lyso-thermosensitive | 1 |
| 355 | masuri | 1 |
| 356 | maximal-dose | 11 |
| 357 | maximum-dose | 12 |
| 358 | mdd/no | 2 |
| 359 | mechanico-chemical | 2 |
| 360 | medium-dose | 79 |
| 361 | megadose | 9 |
| 362 | mek-inhibitor | 1 |
| 363 | methods-low-dose | 1 |
| 364 | methotrexate- | 2 |
| 365 | methotrexate/vinblastine/doxorubicin/cisplatin | 2 |
| 366 | micro-dose | 3 |
| 367 | microemulsified | 2 |
| 368 | microneedling-assisted | 1 |
| 369 | micronisedfeno | 1 |
| 370 | mid-dose | 22 |
| 371 | mid-intensity | 2 |
| 372 | mid-potency | 5 |
| 373 | middle-dose | 29 |
| 374 | mini-dose | 4 |
| 375 | minidose | 18 |
| 376 | mirabilis.the | 1 |
| 377 | mmlv | 4 |
| 378 | mn-assisted | 1 |
| 379 | moderate-dosage | 7 |
| 380 | moderate-dose | 82 |
| 381 | moderate-potency | 3 |
| 382 | moderate-to-high-dose | 1 |
| 383 | monitored-dose | 2 |
| 384 | mono-component | 3 |
| 385 | monooleate-modified | 1 |
| 386 | monthly-dose | 1 |
| 387 | more-soluble | 1 |
| 388 | morning-dosed | 3 |
| 389 | morning-only | 11 |
| 390 | mtx+high-dose | 1 |
| 391 | n-desmethyl | 15 |
| 392 | n/l-type | 2 |
| 393 | n=3332 | 1 |
| 394 | n=787 | 1 |
| 395 | narlaprevir/pegylated | 1 |
| 396 | nct01452243 | 1 |
| 397 | ngm-containing | 1 |
| 398 | nightmare-focused | 1 |
| 399 | nighttime-release | 3 |
| 400 | nine-hole | 15 |
| 401 | niox | 4 |
| 402 | nir-responsive | 1 |
| 403 | no-iv | 6 |
| 404 | no-s. | 1 |
| 405 | nociceptin/orphanin | 4 |
| 406 | non-baseline-adjusted | 1 |
| 407 | non-boosted | 4 |
| 408 | non-ca | 3 |
| 409 | non-cabl-inhibitor | 1 |
| 410 | non-cardio-selective | 1 |
| 411 | non-cpg | 3 |
| 412 | non-fractional | 1 |
| 413 | non-fractioned | 1 |
| 414 | non-lipophilic | 2 |
| 415 | non-olmesartan | 2 |
| 416 | non-paa-treated | 7 |
| 417 | non-pegilated | 1 |
| 418 | non-pegylated | 28 |
| 419 | non-pt-based | 3 |
| 420 | non-secondary | 2 |
| 421 | non-wbc-reduced | 6 |
| 422 | nonamino | 1 |
| 423 | nonantioxidant | 1 |
| 424 | nonaspirin | 18 |
| 425 | nonextrafine | 5 |
| 426 | nonimmunosuppressive | 2 |
| 427 | noninactivated | 4 |
| 428 | noniodinized | 1 |
| 429 | nonloading | 3 |
| 430 | nonmaintained | 1 |
| 431 | nonopsonized | 1 |
| 432 | nonpegylated | 9 |
| 433 | nonprotocol | 10 |
| 434 | nonuroselective | 2 |
| 435 | norian | 11 |
| 436 | normal-dose | 18 |
| 437 | nosocomiales | 1 |
| 438 | not-complicated | 3 |
| 439 | nsaids-especially | 1 |
| 440 | ntrk1_ | 3 |
| 441 | oestrogen-only | 8 |
| 442 | off/on | 6 |
| 443 | once-per-week | 6 |
| 444 | once-yearly | 34 |
| 445 | opsonised | 3 |
| 446 | opsonized | 13 |
| 447 | ouverte | 1 |
| 448 | ovariectomised+60mg/kg | 2 |
| 449 | oxaliplatin/lv/infusional | 1 |
| 450 | paa-treated | 7 |
| 451 | palitaxel | 2 |
| 452 | papain-urea | 1 |
| 453 | para-hydroxy | 3 |
| 454 | parent-enhanced | 3 |
| 455 | peg- | 1 |
| 456 | peg-ifn/ | 1 |
| 457 | peg-liposomal | 2 |
| 458 | peg-α-2b | 1 |
| 459 | pegilated | 2 |
| 460 | pegylated | 728 |
| 461 | pf-mouse | 1 |
| 462 | pha-mediated | 1 |
| 463 | pharmacist-participated | 1 |
| 464 | pharmacogenomics-based | 1 |
| 465 | pharmaconutrition-supplemented | 5 |
| 466 | phenoxymethyl | 9 |
| 467 | phenoxymethyl- | 1 |
| 468 | phenytoin-induced | 1 |
| 469 | photofrin™ | 2 |
| 470 | pinggan | 1 |
| 471 | pk-guided | 9 |
| 472 | platinum/ | 1 |
| 473 | platinum/infusional | 1 |
| 474 | pocal | 2 |
| 475 | poldine | 6 |
| 476 | polysulfated | 2 |
| 477 | porcilis | 5 |
| 478 | potassium-wasting | 1 |
| 479 | precirol | 2 |
| 480 | preconception-initiated | 7 |
| 481 | preleukapheresis | 2 |
| 482 | preradiation | 2 |
| 483 | preseasonal | 25 |
| 484 | previous-cycle | 1 |
| 485 | prior/current | 1 |
| 486 | procaine-benzyl | 1 |
| 487 | promiseb® | 1 |
| 488 | prophylactic-dose | 5 |
| 489 | prophylactic/low-dose | 1 |
| 490 | prophylactively | 1 |
| 491 | prrsv-specific | 4 |
| 492 | ps-supported | 2 |
| 493 | pump-driven | 2 |
| 494 | pyridinal | 1 |
| 495 | pyridinyl | 12 |
| 496 | qishen | 9 |
| 497 | radachlorin-mediated | 1 |
| 498 | radiation/oral | 1 |
| 499 | radioinert | 1 |
| 500 | ratio-adjusted | 1 |
| 501 | rbp-supported | 1 |
| 502 | re-formulating | 1 |
| 503 | re-re-treatment | 1 |
| 504 | reduced-dose | 55 |
| 505 | reduced-exposure | 16 |
| 506 | reduced-fluence | 5 |
| 507 | regular-dose | 15 |
| 508 | response-based | 10 |
| 509 | restricted-dose | 3 |
| 510 | res±perioperative | 1 |
| 511 | review.peri-implantation | 1 |
| 512 | revivable | 1 |
| 513 | ribavirin-pegylated | 1 |
| 514 | ribavirine-standard | 1 |
| 515 | risk-indicated | 1 |
| 516 | ritonavir-boosted | 154 |
| 517 | ritonavir-enhanced | 3 |
| 518 | rpv+ftc/ | 1 |
| 519 | rs-expressing | 1 |
| 520 | rt-bound | 1 |
| 521 | rumination-focused | 5 |
| 522 | sag-induced | 1 |
| 523 | same-time-daily | 1 |
| 524 | secura | 1 |
| 525 | sehi | 5 |
| 526 | semi-bespoke | 3 |
| 527 | short-course | 367 |
| 528 | short-term/no | 1 |
| 529 | silylated | 8 |
| 530 | simvastatin/ | 1 |
| 531 | single-coil | 6 |
| 532 | single-course | 16 |
| 533 | single-inhaler | 8 |
| 534 | site-activated | 1 |
| 535 | small-dose | 23 |
| 536 | small-particle-size | 1 |
| 537 | smartphone-supplemented | 3 |
| 538 | sodic | 2 |
| 539 | sofzia-preserved | 3 |
| 540 | solvent-based | 16 |
| 541 | sorafenib+ | 2 |
| 542 | soy/whey | 9 |
| 543 | spect/low-dose | 2 |
| 544 | speech-enabled | 1 |
| 545 | spironolactone-analogue | 1 |
| 546 | split-dose | 103 |
| 547 | ss/tr | 2 |
| 548 | stable-dose | 19 |
| 549 | staff-led | 5 |
| 550 | standard-dose | 456 |
| 551 | standard-duration | 9 |
| 552 | standard-exposure | 10 |
| 553 | standard-fluence | 4 |
| 554 | standard-intensity | 8 |
| 555 | standard-lose | 1 |
| 556 | standard-maintenance-dose | 2 |
| 557 | stellarex | 1 |
| 558 | stress-dose | 4 |
| 559 | subcutanous | 1 |
| 560 | subtitled | 1 |
| 561 | sucabitril | 1 |
| 562 | sufentanil-propofol | 2 |
| 563 | sugared | 17 |
| 564 | sulphadoxine | 7 |
| 565 | supplémentation | 19 |
| 566 | supraselective | 1 |
| 567 | surgimesh | 1 |
| 568 | svv-based | 1 |
| 569 | synthetic-source | 5 |
| 570 | systemically-used | 3 |
| 571 | taxol+ | 2 |
| 572 | tdf+ | 2 |
| 573 | telomere-targeting | 1 |
| 574 | temoporfin | 2 |
| 575 | tenofovir+ | 1 |
| 576 | tenofovir/ | 2 |
| 577 | test-side | 1 |
| 578 | testosterone-like | 1 |
| 579 | time-modified | 1 |
| 580 | tolerability-adapted | 1 |
| 581 | tor-i/reduced | 1 |
| 582 | tor-i/standard-dose | 1 |
| 583 | traditional/customized | 1 |
| 584 | transcolonic | 3 |
| 585 | trichdb | 1 |
| 586 | triple-dose | 6 |
| 587 | triweekly | 22 |
| 588 | twenty-unit | 1 |
| 589 | twenty-week | 1 |
| 590 | two-pill | 14 |
| 591 | tyrosinkinase-inhibitor | 1 |
| 592 | u.s.-approved | 4 |
| 593 | ultra-low-dose | 24 |
| 594 | ultra-low-molecular-weight | 4 |
| 595 | ultra-potent | 1 |
| 596 | ultrafluid | 1 |
| 597 | ultralow-dose | 6 |
| 598 | unaccepting | 6 |
| 599 | unboosted | 43 |
| 600 | undeuterated | 1 |
| 601 | unfractionated | 760 |
| 602 | unfractioned | 16 |
| 603 | urease-deficient | 5 |
| 604 | usual-dose | 15 |
| 605 | usual-intensity | 1 |
| 606 | vascu-guard | 10 |
| 607 | vasopressinase-resistant | 2 |
| 608 | vbn-assisted | 8 |
| 609 | vector-delivered | 1 |
| 610 | vectormune | 4 |
| 611 | ventilator-derived | 2 |
| 612 | verteporfin/sham | 1 |
| 613 | very-low-dose | 7 |
| 614 | vsv-induced | 1 |
| 615 | vtd-induced | 1 |
| 616 | whole-neck | 2 |
| 617 | xeliri- | 1 |
| 618 | yifei | 1 |
| 619 | yinzhihuang | 11 |
| 620 | z-cut | 3 |
| 621 | zolpidem/ | 1 |
| 622 | β₃-adrenoceptor-selective | 2 |
| 623 | ≥64-multidetector | 1 |
| 1 | 0.97* | 1 |
| 2 | sorafenib+ | 2 |
| 3 | ac+ | 1 |
| 4 | ceftazidime+ | 1 |
| 5 | tdf+ | 2 |
| 6 | inf+ | 1 |
| 7 | 2nrti+ | 1 |
| 8 | taxol+ | 2 |
| 9 | tenofovir+ | 1 |
| 10 | methotrexate- | 2 |
| 11 | peg- | 1 |
| 12 | xeliri- | 1 |
| 13 | phenoxymethyl- | 1 |
| 14 | 25-o-desacetyl- | 1 |
| 15 | 8-isoprostan- | 1 |
| 16 | gabapentin- | 1 |
| 17 | azt- | 2 |
| 18 | no-s. | 1 |
| 19 | arb/ | 1 |
| 20 | rpv+ftc/ | 1 |
| 21 | ezetimibe/ | 2 |
| 22 | dopamine/ | 1 |
| 23 | atv/r+tdf/ | 1 |
| 24 | acei/ | 2 |
| 25 | lisinopril/ | 1 |
| 26 | alcohol/ | 1 |
| 27 | zolpidem/ | 1 |
| 28 | platinum/ | 1 |
| 29 | losartan/ | 2 |
| 30 | aliskiren/ | 1 |
| 31 | peg-ifn/ | 1 |
| 32 | cisplatin/ | 2 |
| 33 | simvastatin/ | 1 |
| 34 | ern/ | 1 |
| 35 | atazanavir/ | 1 |
| 36 | tenofovir/ | 2 |
| 37 | 1:1.850,000 | 1 |
| 38 | 1:1.850.000 | 1 |
| 39 | alpha-fox3000 | 1 |
| 40 | 43,810 | 1 |
| 41 | 32,050 | 1 |
| 42 | ct1-2n0 | 1 |
| 43 | litre-1 | 1 |
| 44 | n=3332 | 1 |
| 45 | 225,952 | 1 |
| 46 | 19,872 | 1 |
| 47 | 20mg/m2 | 1 |
| 48 | 49/103 | 1 |
| 49 | nct01452243 | 1 |
| 50 | 12,324 | 1 |
| 51 | 158,054 | 1 |
| 52 | 135/0.5 | 1 |
| 53 | 12.2±0.5 | 1 |
| 54 | 284:1008-1015 | 1 |
| 55 | 60/5/35 | 1 |
| 56 | 30/25/45 | 1 |
| 57 | 53,565 | 2 |
| 58 | 95,765 | 1 |
| 59 | 135/0.75 | 1 |
| 60 | 99,926 | 1 |
| 61 | 4,927 | 1 |
| 62 | 36,037 | 1 |
| 63 | n=787 | 1 |
| 64 | 387,268 | 1 |
| 65 | 25/678 | 1 |
| 66 | 4.1±2.9 | 1 |
| 67 | 5389 | 1 |
| 68 | ntrk1_ | 3 |
| 69 | non-ca | 3 |
| 70 | 5-kda | 1 |
| 71 | papain-urea | 1 |
| 72 | hospira | 19 |
| 73 | secura | 1 |
| 74 | cooperativa | 1 |
| 75 | peg-α-2b | 1 |
| 76 | trichdb | 1 |
| 77 | 10-iu/cc | 1 |
| 78 | sodic | 2 |
| 79 | prrsv-specific | 4 |
| 80 | antihaemophilic | 1 |
| 81 | non-lipophilic | 2 |
| 82 | hvj-anionic | 1 |
| 83 | transcolonic | 3 |
| 84 | lantiobiotic | 1 |
| 85 | eubiotic | 1 |
| 86 | kystic | 1 |
| 87 | hib-menc | 5 |
| 88 | double-arc | 3 |
| 89 | dual-arc | 1 |
| 90 | 1-100mg/d | 1 |
| 91 | immune-enhanced | 4 |
| 92 | biofeedback-enhanced | 2 |
| 93 | ritonavir-enhanced | 3 |
| 94 | parent-enhanced | 3 |
| 95 | 3alpha-reduced | 7 |
| 96 | non-wbc-reduced | 6 |
| 97 | buffy-coat-reduced | 4 |
| 98 | tor-i/reduced | 1 |
| 99 | anti-mhc-induced | 1 |
| 100 | vtd-induced | 1 |
| 101 | sag-induced | 1 |
| 102 | phenytoin-induced | 1 |
| 103 | vsv-induced | 1 |
| 104 | hyperproduced | 1 |
| 105 | glutamine-added | 2 |
| 106 | b-ultrasound-guided | 7 |
| 107 | aai-guided | 2 |
| 108 | fmri-guided | 8 |
| 109 | pk-guided | 9 |
| 110 | aminoacid-enriched | 3 |
| 111 | igm-enriched | 24 |
| 112 | eclectic/unspecified | 1 |
| 113 | time-modified | 1 |
| 114 | galactose-modified | 1 |
| 115 | monooleate-modified | 1 |
| 116 | microemulsified | 2 |
| 117 | staff-led | 5 |
| 118 | speech-enabled | 1 |
| 119 | 99tcm-labelled | 1 |
| 120 | hfa-propelled | 6 |
| 121 | subtitled | 1 |
| 122 | nonmaintained | 1 |
| 123 | inverse-planned | 2 |
| 124 | non-fractioned | 1 |
| 125 | unfractioned | 16 |
| 126 | sugared | 17 |
| 127 | arrhythmia-triggered | 2 |
| 128 | vector-delivered | 1 |
| 129 | chinese-authored | 1 |
| 130 | genentech-sponsored | 1 |
| 131 | chickpea-based | 3 |
| 132 | ala-based | 2 |
| 133 | anti-fxa-based | 1 |
| 134 | iopromide-based | 2 |
| 135 | l-asparaginase-based | 4 |
| 136 | response-based | 10 |
| 137 | gauze-based | 15 |
| 138 | f-based | 2 |
| 139 | flurouracil-based | 2 |
| 140 | estradiol-based | 4 |
| 141 | pharmacogenomics-based | 1 |
| 142 | solvent-based | 16 |
| 143 | non-pt-based | 3 |
| 144 | 3d-crt-based | 1 |
| 145 | bu-based | 2 |
| 146 | svv-based | 1 |
| 147 | opsonised | 3 |
| 148 | double-dosed | 1 |
| 149 | morning-dosed | 3 |
| 150 | systemically-used | 3 |
| 151 | locally-used | 3 |
| 152 | nightmare-focused | 1 |
| 153 | rumination-focused | 5 |
| 154 | cp-focused | 1 |
| 155 | cognitively-focused | 1 |
| 156 | risk-indicated | 1 |
| 157 | not-complicated | 3 |
| 158 | paa-treated | 7 |
| 159 | non-paa-treated | 7 |
| 160 | hbr-pre-treated | 2 |
| 161 | polysulfated | 2 |
| 162 | jak1-mediated | 1 |
| 163 | pha-mediated | 1 |
| 164 | ala-mediated | 1 |
| 165 | afxl-mediated | 1 |
| 166 | radachlorin-mediated | 1 |
| 167 | daylight-mediated | 19 |
| 168 | preconception-initiated | 7 |
| 169 | pegilated | 2 |
| 170 | non-pegilated | 1 |
| 171 | dithiolated | 1 |
| 172 | leucovorin-modulated | 2 |
| 173 | calcimycin-stimulated | 2 |
| 174 | coformulated | 25 |
| 175 | pegylated | 728 |
| 176 | ribavirin-pegylated | 1 |
| 177 | carboplatin-pegylated | 6 |
| 178 | non-pegylated | 28 |
| 179 | carboplatin/pegylated | 1 |
| 180 | interferon/pegylated | 1 |
| 181 | narlaprevir/pegylated | 1 |
| 182 | nonpegylated | 9 |
| 183 | c17alpha-alkylated | 2 |
| 184 | silylated | 8 |
| 185 | unfractionated | 760 |
| 186 | eudragit-l-coated | 2 |
| 187 | pharmacist-participated | 1 |
| 188 | undeuterated | 1 |
| 189 | insulin-titrated | 1 |
| 190 | site-activated | 1 |
| 191 | noninactivated | 4 |
| 192 | investigator-selected | 14 |
| 193 | european-marketed | 5 |
| 194 | appropriately-implemented | 1 |
| 195 | glutamine-supplemented | 22 |
| 196 | l-alanyl-l-glutamine-supplemented | 1 |
| 197 | smartphone-supplemented | 3 |
| 198 | pharmaconutrition-supplemented | 5 |
| 199 | dose-adapted | 1 |
| 200 | tolerability-adapted | 1 |
| 201 | rbp-supported | 1 |
| 202 | ps-supported | 2 |
| 203 | microneedling-assisted | 1 |
| 204 | fl-assisted | 1 |
| 205 | ipl-assisted | 1 |
| 206 | afxl-assisted | 4 |
| 207 | vbn-assisted | 8 |
| 208 | mn-assisted | 1 |
| 209 | non-boosted | 4 |
| 210 | ritonavir-boosted | 154 |
| 211 | cobicistat-boosted | 2 |
| 212 | unboosted | 43 |
| 213 | non-baseline-adjusted | 1 |
| 214 | dose-adjusted | 62 |
| 215 | ratio-adjusted | 1 |
| 216 | inr-adjusted | 2 |
| 217 | 1-silyl-substituted | 1 |
| 218 | fukushima-derived | 3 |
| 219 | ventilator-derived | 2 |
| 220 | u.s.-approved | 4 |
| 221 | investigator-approved | 1 |
| 222 | sofzia-preserved | 3 |
| 223 | cyp3a4-metabolized | 9 |
| 224 | traditional/customized | 1 |
| 225 | noniodinized | 1 |
| 226 | opsonized | 13 |
| 227 | nonopsonized | 1 |
| 228 | beta-hydroxyacid | 1 |
| 229 | ultrafluid | 1 |
| 230 | 4-field | 1 |
| 231 | 5-field | 3 |
| 232 | 9-field | 2 |
| 233 | extended-field | 12 |
| 234 | five-field | 3 |
| 235 | rt-bound | 1 |
| 236 | ribavirine-standard | 1 |
| 237 | vascu-guard | 10 |
| 238 | 10.000e | 1 |
| 239 | chronice | 1 |
| 240 | high-compliance | 3 |
| 241 | reduced-fluence | 5 |
| 242 | standard-fluence | 4 |
| 243 | high-fluence | 6 |
| 244 | low-fluence | 50 |
| 245 | synthetic-source | 5 |
| 246 | control-side | 1 |
| 247 | test-side | 1 |
| 248 | 14-peptide | 1 |
| 249 | aminoacid-free | 2 |
| 250 | cysteine-free | 5 |
| 251 | efavirenz-free | 6 |
| 252 | moderate-dosage | 7 |
| 253 | high-dosage | 60 |
| 254 | low-dosage | 51 |
| 255 | fine-gauge | 1 |
| 256 | mirabilis.the | 1 |
| 257 | high-protein/calorie | 1 |
| 258 | high-nacl-intake | 1 |
| 259 | low-nacl-intake | 1 |
| 260 | testosterone-like | 1 |
| 261 | semi-bespoke | 3 |
| 262 | revivable | 1 |
| 263 | more-soluble | 1 |
| 264 | four-cycle | 2 |
| 265 | previous-cycle | 1 |
| 266 | 9-hole | 6 |
| 267 | nine-hole | 15 |
| 268 | biotene | 9 |
| 269 | cetacaine | 2 |
| 270 | poldine | 6 |
| 271 | biafine | 1 |
| 272 | nonextrafine | 5 |
| 273 | benzathine | 67 |
| 274 | banzanthine | 1 |
| 275 | benzanthine | 1 |
| 276 | sulphadoxine | 7 |
| 277 | bupivacaine/hydromorphone | 2 |
| 278 | vectormune | 4 |
| 279 | n/l-type | 2 |
| 280 | dual-hemisphere | 4 |
| 281 | easy-to-store | 1 |
| 282 | biopure | 10 |
| 283 | reduced-exposure | 16 |
| 284 | standard-exposure | 10 |
| 285 | low-exposure | 13 |
| 286 | nighttime-release | 3 |
| 287 | prophylactic-dose | 5 |
| 288 | reduced-dose | 55 |
| 289 | extended-dose | 17 |
| 290 | monitored-dose | 2 |
| 291 | increased-dose | 6 |
| 292 | escalated-dose | 17 |
| 293 | restricted-dose | 3 |
| 294 | adjusted-dose | 79 |
| 295 | mid-dose | 22 |
| 296 | standard-dose | 456 |
| 297 | tor-i/standard-dose | 1 |
| 298 | standard-maintenance-dose | 2 |
| 299 | high-maintenance-dose | 3 |
| 300 | stable-dose | 19 |
| 301 | adjustable-dose | 1 |
| 302 | double-dose | 76 |
| 303 | middle-dose | 29 |
| 304 | triple-dose | 6 |
| 305 | intermediate-dose | 51 |
| 306 | moderate-dose | 82 |
| 307 | intensive-dose | 30 |
| 308 | half-dose | 119 |
| 309 | corresponding-dose | 5 |
| 310 | high-dose | 4,667 |
| 311 | mtx+high-dose | 1 |
| 312 | moderate-to-high-dose | 1 |
| 313 | mini-dose | 4 |
| 314 | maximal-dose | 11 |
| 315 | normal-dose | 18 |
| 316 | conventional-dose | 73 |
| 317 | usual-dose | 15 |
| 318 | small-dose | 23 |
| 319 | full-dose | 172 |
| 320 | medium-dose | 79 |
| 321 | maximum-dose | 12 |
| 322 | micro-dose | 3 |
| 323 | regular-dose | 15 |
| 324 | higher-dose | 119 |
| 325 | lower-dose | 111 |
| 326 | stress-dose | 4 |
| 327 | split-dose | 103 |
| 328 | low-dose | 5,273 |
| 329 | 5-fu+low-dose | 3 |
| 330 | ultra-low-dose | 24 |
| 331 | methods-low-dose | 1 |
| 332 | very-low-dose | 7 |
| 333 | prophylactic/low-dose | 1 |
| 334 | aspirin/low-dose | 1 |
| 335 | spect/low-dose | 2 |
| 336 | ultralow-dose | 6 |
| 337 | baby-dose | 1 |
| 338 | monthly-dose | 1 |
| 339 | megadose | 9 |
| 340 | highdose | 4 |
| 341 | minidose | 18 |
| 342 | low‑dose | 7 |
| 343 | standard-lose | 1 |
| 344 | single-course | 16 |
| 345 | short-course | 367 |
| 346 | pf-mouse | 1 |
| 347 | appropriate/inappropriate | 1 |
| 348 | high-dose-rate | 34 |
| 349 | ouverte | 1 |
| 350 | spironolactone-analogue | 1 |
| 351 | longwave | 1 |
| 352 | nir-responsive | 1 |
| 353 | keratotic-atrophic-erosive | 1 |
| 354 | nonimmunosuppressive | 2 |
| 355 | 14-3-3σ-negative | 1 |
| 356 | res±perioperative | 1 |
| 357 | full-laxative | 4 |
| 358 | non-cardio-selective | 1 |
| 359 | β₃-adrenoceptor-selective | 2 |
| 360 | supraselective | 1 |
| 361 | nonuroselective | 2 |
| 362 | corrispective | 1 |
| 363 | lyso-thermosensitive | 1 |
| 364 | 14-3-3σ-positive | 1 |
| 365 | 2-size | 1 |
| 366 | small-particle-size | 1 |
| 367 | actief | 1 |
| 368 | 6.8-g | 3 |
| 369 | 500iu/g | 1 |
| 370 | 2.0g | 2 |
| 371 | 1.0-mg/kg | 3 |
| 372 | 1-mg/kg | 6 |
| 373 | ovariectomised+60mg/kg | 2 |
| 374 | delta-tocotrienol+11mg/kg | 1 |
| 375 | 7mg/kg | 2 |
| 376 | 135-microg/kg | 2 |
| 377 | 100u/kg | 1 |
| 378 | 70u/kg | 2 |
| 379 | 2×100-mg | 6 |
| 380 | 1.2-mg | 2 |
| 381 | 0.3-mg | 21 |
| 382 | 333-mg | 1 |
| 383 | 54-mg | 2 |
| 384 | 3.5-mg | 7 |
| 385 | 1.75-mg | 3 |
| 386 | 0mg | 9 |
| 387 | buchang | 3 |
| 388 | yinzhihuang | 11 |
| 389 | elastic-tubing | 1 |
| 390 | nonloading | 3 |
| 391 | eliminating-avoiding | 1 |
| 392 | hema-containing | 1 |
| 393 | cocaine-containing | 2 |
| 394 | barbiturate-containing | 2 |
| 395 | desogestrel-containing | 3 |
| 396 | ngm-containing | 1 |
| 397 | copperbearing | 2 |
| 398 | luciferase-expressing | 1 |
| 399 | rs-expressing | 1 |
| 400 | re-formulating | 1 |
| 401 | co-administrating | 2 |
| 402 | telomere-targeting | 1 |
| 403 | elliciting | 1 |
| 404 | unaccepting | 6 |
| 405 | potassium-wasting | 1 |
| 406 | dose-intensifying | 2 |
| 407 | buzhong | 2 |
| 408 | 700-microg | 4 |
| 409 | 350-microg | 1 |
| 410 | 44-microg | 1 |
| 411 | non-cpg | 3 |
| 412 | 50-µg | 2 |
| 413 | 600-μg | 4 |
| 414 | 20-μg | 7 |
| 415 | 80-μg | 5 |
| 416 | 100μg | 7 |
| 417 | 30μg | 5 |
| 418 | 2μg | 1 |
| 419 | surgimesh | 1 |
| 420 | calf-thigh-length | 1 |
| 421 | yifei | 1 |
| 422 | sehi | 5 |
| 423 | masuri | 1 |
| 424 | antivitamin-k | 2 |
| 425 | whole-neck | 2 |
| 426 | every-12-week | 2 |
| 427 | every-3-week | 9 |
| 428 | every-4-week | 4 |
| 429 | alternate-week | 5 |
| 430 | every-other-week | 13 |
| 431 | once-per-week | 6 |
| 432 | twenty-week | 1 |
| 433 | 2-l | 48 |
| 434 | 4-l | 56 |
| 435 | 0.5mm/l | 1 |
| 436 | 3+1l | 1 |
| 437 | antistaphlococcal | 1 |
| 438 | mechanico-chemical | 2 |
| 439 | pocal | 2 |
| 440 | esencial | 2 |
| 441 | peg-liposomal | 2 |
| 442 | pyridinal | 1 |
| 443 | infusional | 179 |
| 444 | platinum/infusional | 1 |
| 445 | oxaliplatin/lv/infusional | 1 |
| 446 | non-fractional | 1 |
| 447 | preseasonal | 25 |
| 448 | cheliceral | 1 |
| 449 | aza/oral | 1 |
| 450 | radiation/oral | 1 |
| 451 | cut-off=intermediate-level | 1 |
| 452 | cut-off=low-level | 1 |
| 453 | palitaxel | 2 |
| 454 | single-coil | 6 |
| 455 | sucabitril | 1 |
| 456 | two-pill | 14 |
| 457 | high-pull | 3 |
| 458 | 0.03iu/ml | 1 |
| 459 | 2ml | 15 |
| 460 | nonprotocol | 10 |
| 461 | sufentanil-propofol | 2 |
| 462 | precirol | 2 |
| 463 | 25-o-desacteyl | 1 |
| 464 | 5-methyl | 14 |
| 465 | dl-15-methyl | 1 |
| 466 | n-desmethyl | 15 |
| 467 | phenoxymethyl | 9 |
| 468 | 4'-hydroxyphenyl | 3 |
| 469 | pyridinyl | 12 |
| 470 | 1-hexylcarbamoyl | 1 |
| 471 | behenoyl | 2 |
| 472 | 25-o-desacetyl | 2 |
| 473 | procaine-benzyl | 1 |
| 474 | alpha-amino-p-hydroxybenzyl | 1 |
| 475 | 0.5m | 7 |
| 476 | verteporfin/sham | 1 |
| 477 | c-stem | 5 |
| 478 | 0.1-10mm | 1 |
| 479 | 3-ppm | 2 |
| 480 | 100-µm | 2 |
| 481 | 700-900-μm | 1 |
| 482 | 75μm | 2 |
| 483 | d4t+3tc+an | 1 |
| 484 | azt+3tc+an | 1 |
| 485 | irbesartan-an | 1 |
| 486 | pinggan | 1 |
| 487 | chan | 45 |
| 488 | norian | 11 |
| 489 | gfp-human | 1 |
| 490 | non-olmesartan | 2 |
| 491 | hanchuan | 1 |
| 492 | qishen | 9 |
| 493 | huadananshen | 3 |
| 494 | 8-methoxsalen | 1 |
| 495 | pump-driven | 2 |
| 496 | challenge-proven | 1 |
| 497 | temoporfin | 2 |
| 498 | benzathin | 2 |
| 499 | nociceptin/orphanin | 4 |
| 500 | agncs/hairpin | 2 |
| 501 | nonaspirin | 18 |
| 502 | methotrexate/vinblastine/doxorubicin/cisplatin | 2 |
| 503 | dermatotoxin | 1 |
| 504 | off/on | 6 |
| 505 | gaviscon | 46 |
| 506 | continuous-infusion | 34 |
| 507 | preradiation | 2 |
| 508 | firstgeneration | 1 |
| 509 | creams.high-concentration | 1 |
| 510 | standard-duration | 9 |
| 511 | review.peri-implantation | 1 |
| 512 | arginine-supplementation | 2 |
| 513 | supplémentation | 19 |
| 514 | 1-gallon | 4 |
| 515 | intrapartum/newborn | 1 |
| 516 | decrescendo | 4 |
| 517 | mdd/no | 2 |
| 518 | low-dose/no | 2 |
| 519 | short-term/no | 1 |
| 520 | micronisedfeno | 1 |
| 521 | nonamino | 1 |
| 522 | hi-trap | 2 |
| 523 | 1-drop | 2 |
| 524 | kefar | 1 |
| 525 | kfar | 1 |
| 526 | long-acting-intramuscular | 1 |
| 527 | kevlar | 1 |
| 528 | aspirin-er | 3 |
| 529 | single-inhaler | 8 |
| 530 | aspiriner | 1 |
| 531 | 130-nanometer | 1 |
| 532 | headaches.for | 1 |
| 533 | d-panor | 1 |
| 534 | ≥64-multidetector | 1 |
| 535 | tyrosinkinase-inhibitor | 1 |
| 536 | mek-inhibitor | 1 |
| 537 | non-cabl-inhibitor | 1 |
| 538 | ebrtor | 1 |
| 539 | ss/tr | 2 |
| 540 | nosocomiales | 1 |
| 541 | porcilis | 5 |
| 542 | preleukapheresis | 2 |
| 543 | electroforesis | 1 |
| 544 | 900-1200/micrograms | 1 |
| 545 | compañeros | 1 |
| 546 | baypress | 3 |
| 547 | double-bolus | 5 |
| 548 | subcutanous | 1 |
| 549 | epirubicin-cisplatin-continuous | 1 |
| 550 | analgesia.continuous | 1 |
| 551 | candys | 5 |
| 552 | low-molecular-weight | 601 |
| 553 | ultra-low-molecular-weight | 4 |
| 554 | heparin/low-molecular-weight | 1 |
| 555 | twenty-unit | 1 |
| 556 | nonantioxidant | 1 |
| 557 | intensity-deviant | 1 |
| 558 | vasopressinase-resistant | 2 |
| 559 | urease-deficient | 5 |
| 560 | re-re-treatment | 1 |
| 561 | full-treatment | 1 |
| 562 | mono-component | 3 |
| 563 | prior/current | 1 |
| 564 | ultra-potent | 1 |
| 565 | algorithm-consistent | 3 |
| 566 | conventional-start | 4 |
| 567 | radioinert | 1 |
| 568 | z-cut | 3 |
| 569 | 300-u | 5 |
| 570 | 4000iu | 7 |
| 571 | 500iu | 2 |
| 572 | kangliu | 2 |
| 573 | blu | 9 |
| 574 | no-iv | 6 |
| 575 | cisplatin/iv | 1 |
| 576 | mmlv | 4 |
| 577 | 14w | 5 |
| 578 | lmw | 118 |
| 579 | adequate-to-low | 1 |
| 580 | ceram-x | 3 |
| 581 | stellarex | 1 |
| 582 | cotex | 1 |
| 583 | lutonix | 7 |
| 584 | niox | 4 |
| 585 | alternate-day | 83 |
| 586 | 50-mg/day | 2 |
| 587 | 90-mg/day | 2 |
| 588 | 0.625-mg/day | 1 |
| 589 | higher-efficacy | 1 |
| 590 | mid-potency | 5 |
| 591 | moderate-potency | 3 |
| 592 | high-potency | 80 |
| 593 | intermediate-/high-potency | 1 |
| 594 | caprie-study | 1 |
| 595 | soy/whey | 9 |
| 596 | 74-gy | 1 |
| 597 | 45-gy | 2 |
| 598 | prophylactively | 1 |
| 599 | same-time-daily | 1 |
| 600 | five-times-daily | 2 |
| 601 | triweekly | 22 |
| 602 | nsaids-especially | 1 |
| 603 | anthracycline-only | 3 |
| 604 | morning-only | 11 |
| 605 | oestrogen-only | 8 |
| 606 | once-yearly | 34 |
| 607 | clopidogrel/dummy | 1 |
| 608 | non-secondary | 2 |
| 609 | immunosuppressant/anti-inflammatory | 1 |
| 610 | mid-intensity | 2 |
| 611 | standard-intensity | 8 |
| 612 | usual-intensity | 1 |
| 613 | 2-hydroxy | 13 |
| 614 | 5-hydroxy | 7 |
| 615 | 9-hydroxy | 5 |
| 616 | para-hydroxy | 3 |
| 617 | cip/mtz | 6 |
| 618 | cbz→ | 1 |
| 619 | photofrin™ | 2 |
| 620 | elusion™ | 1 |
| 621 | promiseb® | 1 |
| 622 | kollidon® | 5 |
| 623 | compounds׳ | 1 |